Drug Profile
PF 3758309
Alternative Names: PF-03758309; PF-309; PF-3758309Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antineoplastics; Small molecules
- Mechanism of Action P21 activated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 16 Nov 2011 Adverse events and pharmacokinetics data from a phase I trial in Solid tumours presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-EORTC-NCI-2011)
- 10 Nov 2011 Discontinued - Phase-I for Solid tumours in Australia (PO)
- 10 Nov 2011 Discontinued - Phase-I for Solid tumours in USA (PO)